RxDoctor Payments Data

Carolyn Indianos, MD

Family Medicine · Jacksonville, FLNPI 1992298608

Payments from drug & device makers

$2,607in general payments, 2019–2025

Across 119 payments — averaging $21.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$747
  • Merz North America, Inc.$201
  • Exact Sciences$200
  • GSK$197
  • Lilly USA, LLC$190
  • Novo Nordisk$184
  • plus $888 from 19 others

What the payments were for

  • Food & beverage$2,607100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,607 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$17,592
Medicare patients
67
Services billed
275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$36,049
MounjaroTirzepatide30$30,786
EliquisApixaban18$24,067
Celecoxib40$6,711
Pregabalin28$3,297
Gabapentin155$3,062
Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort28$2,813
Albuterol Sulfate HfaAlbuterol Sulfate105$2,006
Baclofen107$1,696
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$1,659
Atorvastatin Calcium192$1,627
Oxybutynin Chloride ErOxybutynin Chloride40$1,578
Buspirone Hcl62$1,497
Diclofenac Sodium20$1,437
Levothyroxine Sodium88$1,133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$197$36,04945 claims
Lilly USA, LLCMounjaro$190$30,78630 claims
PfizerEliquis$121$24,06718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →